secwatch.observer — SEC 8-K summary
======================================

Issuer:     Finch Therapeutics Group, Inc. (FNCHQ)
CIK:        0001733257
Form:       8-K
Filed at:   2022-06-16T23:59:59+00:00
Accession:  0000950170-22-011723
Event type: other
Sentiment:  neutral
Materiality: 0.10
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Finch Therapeutics stockholders elect three Class I directors and ratify Deloitte as auditor
--------------------------------------------------------------------------------

- 36,785,341 shares (77.35% of outstanding) present at June 10, 2022 annual meeting.
- Domenic Ferrante, Nicholas Haft, Samuel A. Hamood elected as Class I directors with >26.8M votes for each.
- Ratification of Deloitte & Touche as auditor for FY2022 approved: 36,759,831 for, 20,585 against.
- Broker non-votes of 7,987,710 on director election; none on auditor ratification.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1733257/000095017022011723/0000950170-22-011723-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1733257/000095017022011723/fnch-20220610.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-011723

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer